Sirturo is a tuberculosis medicine that contains the active substance bedaquiline. Tuberculosis is an infection caused by the bacterium Mycobacterium tuberculosis. Sirturo is used in combination with other tuberculosis medicines in adults and children (aged 5 years and older and weighing at least 15 kg) with tuberculosis in the lung that is resistant to at least isoniazid and rifampicin, the two standard tuberculosis medicines.
Therapeutic Indication
### Therapeutic indication Sirturo is indicated for use as part of an appropriate combination regimen in adult and paediatric patients (5 years to less than 18 years of age and weighing at least 15 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampicin and isoniazid. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Therapeutic Area (MeSH)
ATC Code
J04AK05
ATC Item
bedaquiline
Pharmacotherapeutic Group
bedaquiline
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| bedaquiline fumarate | N/A | Bedaquiline Fumarate |
EMA Name
Sirturo
Medicine Name
Sirturo
Aliases
N/ANo risk management plan link.
